Selected research
Market Structure
Global CGT Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global CGT Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of CGT Drugs include Bluebird Bio, Celgene Corporation, Juno Therapeutics, Kite Pharma, Orchard Therapeutics, Spark Therapeutics, Amgen, Fosun Kite Biotechnology and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global CGT Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of CGT Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents CGT Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the CGT Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
CGT Drugs Segment by Company
Bluebird Bio
Celgene Corporation
Juno Therapeutics
Kite Pharma
Orchard Therapeutics
Spark Therapeutics
Amgen
Fosun Kite Biotechnology
GSK
Novartis
SiBiono
Sunway Biotech
Janssen Biotech
Sequoia
CGT Drugs Segment by Type
CAR-T Therapy
Viral Vector Therapy
Stem Cell Therapy
Oncolytic Virus Therapy
CGT Drugs Segment by Application
Tumor Disease
Eye Disease
Rare Disease
Others
CGT Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGT Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGT Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGT Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the CGT Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CGT Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of CGT Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- CAR-T Therapy
- Viral Vector Therapy
- Stem Cell Therapy
- Oncolytic Virus Therapy
Applications
- Tumor Disease
- Eye Disease
- Rare Disease
- Others
Companies covered
- Bluebird Bio
- Celgene Corporation
- Juno Therapeutics
- Kite Pharma
- Orchard Therapeutics
- Spark Therapeutics
- Amgen
- Fosun Kite Biotechnology
- GSK
- Novartis
- SiBiono
- Sunway Biotech
- Janssen Biotech
- Sequoia
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global CGT Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global CGT Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global CGT Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global CGT Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global CGT Drugs Market Dynamics
- 2.1 CGT Drugs Industry Trends
- 2.2 CGT Drugs Industry Drivers
- 2.3 CGT Drugs Industry Opportunities and Challenges
- 2.4 CGT Drugs Industry Restraints
3 CGT Drugs Market by Manufacturers
- 3.1 Global CGT Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global CGT Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global CGT Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global CGT Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global CGT Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global CGT Drugs Manufacturers, Product Type & Application
- 3.7 Global CGT Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global CGT Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 CGT Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 CGT Drugs Tier 1, Tier 2, and Tier 3
4 CGT Drugs Market by Type
- 4.1 CGT Drugs Type Introduction
- 4.1.1 CAR-T Therapy
- 4.1.2 Viral Vector Therapy
- 4.1.3 Stem Cell Therapy
- 4.1.4 Oncolytic Virus Therapy
- 4.2 Global CGT Drugs Sales by Type
- 4.2.1 Global CGT Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global CGT Drugs Sales by Type (2021-2032)
- 4.2.3 Global CGT Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global CGT Drugs Revenue by Type
- 4.3.1 Global CGT Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global CGT Drugs Revenue by Type (2021-2032)
- 4.3.3 Global CGT Drugs Revenue Market Share by Type (2021-2032)
5 CGT Drugs Market by Application
- 5.1 CGT Drugs Application Introduction
- 5.1.1 Tumor Disease
- 5.1.2 Eye Disease
- 5.1.3 Rare Disease
- 5.1.4 Others
- 5.2 Global CGT Drugs Sales by Application
- 5.2.1 Global CGT Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global CGT Drugs Sales by Application (2021-2032)
- 5.2.3 Global CGT Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global CGT Drugs Revenue by Application
- 5.3.1 Global CGT Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global CGT Drugs Revenue by Application (2021-2032)
- 5.3.3 Global CGT Drugs Revenue Market Share by Application (2021-2032)
6 Global CGT Drugs Sales by Region
- 6.1 Global CGT Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global CGT Drugs Sales by Region (2021-2032)
- 6.2.1 Global CGT Drugs Sales by Region (2021-2026)
- 6.2.2 Global CGT Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America CGT Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America CGT Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe CGT Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe CGT Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific CGT Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific CGT Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa CGT Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa CGT Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global CGT Drugs Revenue by Region
- 7.1 Global CGT Drugs Revenue by Region
- 7.1.1 Global CGT Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global CGT Drugs Revenue by Region (2021-2026)
- 7.1.3 Global CGT Drugs Revenue by Region (2027-2032)
- 7.1.4 Global CGT Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America CGT Drugs Revenue (2021-2032)
- 7.2.2 North America CGT Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe CGT Drugs Revenue (2021-2032)
- 7.3.2 Europe CGT Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific CGT Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific CGT Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa CGT Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa CGT Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bluebird Bio
- 8.1.1 Bluebird Bio Company Information
- 8.1.2 Bluebird Bio Business Overview
- 8.1.3 Bluebird Bio CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bluebird Bio CGT Drugs Product Portfolio
- 8.1.5 Bluebird Bio Recent Developments
- 8.2 Celgene Corporation
- 8.2.1 Celgene Corporation Company Information
- 8.2.2 Celgene Corporation Business Overview
- 8.2.3 Celgene Corporation CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Celgene Corporation CGT Drugs Product Portfolio
- 8.2.5 Celgene Corporation Recent Developments
- 8.3 Juno Therapeutics
- 8.3.1 Juno Therapeutics Company Information
- 8.3.2 Juno Therapeutics Business Overview
- 8.3.3 Juno Therapeutics CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Juno Therapeutics CGT Drugs Product Portfolio
- 8.3.5 Juno Therapeutics Recent Developments
- 8.4 Kite Pharma
- 8.4.1 Kite Pharma Company Information
- 8.4.2 Kite Pharma Business Overview
- 8.4.3 Kite Pharma CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Kite Pharma CGT Drugs Product Portfolio
- 8.4.5 Kite Pharma Recent Developments
- 8.5 Orchard Therapeutics
- 8.5.1 Orchard Therapeutics Company Information
- 8.5.2 Orchard Therapeutics Business Overview
- 8.5.3 Orchard Therapeutics CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Orchard Therapeutics CGT Drugs Product Portfolio
- 8.5.5 Orchard Therapeutics Recent Developments
- 8.6 Spark Therapeutics
- 8.6.1 Spark Therapeutics Company Information
- 8.6.2 Spark Therapeutics Business Overview
- 8.6.3 Spark Therapeutics CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Spark Therapeutics CGT Drugs Product Portfolio
- 8.6.5 Spark Therapeutics Recent Developments
- 8.7 Amgen
- 8.7.1 Amgen Company Information
- 8.7.2 Amgen Business Overview
- 8.7.3 Amgen CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Amgen CGT Drugs Product Portfolio
- 8.7.5 Amgen Recent Developments
- 8.8 Fosun Kite Biotechnology
- 8.8.1 Fosun Kite Biotechnology Company Information
- 8.8.2 Fosun Kite Biotechnology Business Overview
- 8.8.3 Fosun Kite Biotechnology CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Fosun Kite Biotechnology CGT Drugs Product Portfolio
- 8.8.5 Fosun Kite Biotechnology Recent Developments
- 8.9 GSK
- 8.9.1 GSK Company Information
- 8.9.2 GSK Business Overview
- 8.9.3 GSK CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 GSK CGT Drugs Product Portfolio
- 8.9.5 GSK Recent Developments
- 8.10 Novartis
- 8.10.1 Novartis Company Information
- 8.10.2 Novartis Business Overview
- 8.10.3 Novartis CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Novartis CGT Drugs Product Portfolio
- 8.10.5 Novartis Recent Developments
- 8.11 SiBiono
- 8.11.1 SiBiono Company Information
- 8.11.2 SiBiono Business Overview
- 8.11.3 SiBiono CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 SiBiono CGT Drugs Product Portfolio
- 8.11.5 SiBiono Recent Developments
- 8.12 Sunway Biotech
- 8.12.1 Sunway Biotech Company Information
- 8.12.2 Sunway Biotech Business Overview
- 8.12.3 Sunway Biotech CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Sunway Biotech CGT Drugs Product Portfolio
- 8.12.5 Sunway Biotech Recent Developments
- 8.13 Janssen Biotech
- 8.13.1 Janssen Biotech Company Information
- 8.13.2 Janssen Biotech Business Overview
- 8.13.3 Janssen Biotech CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Janssen Biotech CGT Drugs Product Portfolio
- 8.13.5 Janssen Biotech Recent Developments
- 8.14 Sequoia
- 8.14.1 Sequoia Company Information
- 8.14.2 Sequoia Business Overview
- 8.14.3 Sequoia CGT Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Sequoia CGT Drugs Product Portfolio
- 8.14.5 Sequoia Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 CGT Drugs Value Chain Analysis
- 9.1.1 CGT Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 CGT Drugs Production Mode & Process
- 9.2 CGT Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 CGT Drugs Distributors
- 9.2.3 CGT Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst